

# 1 Protocol on Establishing a National Disease 2 Registry – Swiss Pediatric Inflammatory 3 Brain Disease Registry

4 Swiss Pediatric Inflammatory Brain Disease Registry

5

6 Lorena Freya Hulliger<sup>1</sup>, Anne Tscherter<sup>1</sup>, Claudia Kühni<sup>1</sup>, Sandra Bigi<sup>1,2</sup>,

7 <sup>1</sup>Institute of Social and preventive medicine, University of Bern, Bern, Bern, Switzerland

8 <sup>2</sup>Department of Neuropediatrics, Lucerne cantonal hospital, Children's hospital, Lucerne, Lucerne,

9 Switzerland

## 10 Metadata

### 11 Funding

12 This project is funded by the following organizations: Swiss Multiple Sclerosis Society, Roche Pharma  
13 (Switzerland) Ltd, Novartis Pharma Schweiz AG, and Sanofi-Aventis (Schweiz). The funders had no role in  
14 the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### 15 Competing interests

16 None of the authors have any potentially competing interest to declare.

### 17 Data availability

18 This manuscript is purely technical and does not include any data beyond number of identified potential  
19 study participants and number of signed informed consent forms.

## 20 Abstract

### 21 Background

22 Pediatric-onset inflammatory brain diseases are a group of potentially life-threatening central nervous  
23 system disorders. Overall, pediatric-onset inflammatory brain diseases are rare and therefore difficult to  
24 study. Patient registries are well suited to study the natural history of (rare) diseases and have markedly  
25 advanced the knowledge on pediatric-onset inflammatory brain diseases in other countries. Following  
26 their example, we established a national pediatric-onset inflammatory brain disease registry in  
27 Switzerland (Swiss-Ped-IBrainD).

### 28 Aims

29 The Registry aims to describe epidemiology, demographics, diagnostics, management, and treatment,  
30 since these areas remain understudied in Switzerland. Additionally, we want to promote research by  
31 fostering the knowledge exchange between study centers and setting up studies such as national quality  
32 of life surveys. We further aim to facilitate the access to national and international studies for patients  
33 with a pediatric-onset inflammatory brain disease living and/or treated in Switzerland.

### 34 Methods

35 The Swiss-Ped-IBrainD is a multicentric, population-based, observational cohort study (IRB number:  
36 2019-00377) collaborating with 11 neuropaediatric centers in Switzerland. Patient screening, information  
37 and recruitment is mainly conducted by the local principal investigators. The data collection is organized  
38 centrally by the Executive Office of the registry. The collected data is purely observational. Medical  
39 records are the primary data source. All patients who have been diagnosed with a pediatric-onset  
40 inflammatory brain disease since 2005 are eligible. We aim to include all pediatric-onset inflammatory  
41 brain disease patients living and/or treated in Switzerland who meet the inclusion criteria. Considering  
42 existing literature and our single-center experience we anticipate 300-400 eligible patients.

43 Status

44 Currently, all 11 neuropsychiatric centers have been initiated and are recruiting. As of the first of May

45 2023, we have identified 275 eligible participants and obtained informed consent from 101 patients

46 and/or families. None of the informed patients and/or families have refused participation.

## 47 Introduction

48 Pediatric-onset inflammatory brain diseases (IBrainDs) are rare central nervous system (CNS) diseases  
49 with the potential to cause life-threatening conditions. Often, patients experience an acute initial phase  
50 with neurological symptoms including focal neurological deficits, cognitive and/or behavioral  
51 dysfunctions, seizures, hemiparesis, and ataxia (1, 2).

52 IBrainDs may be primary (idiopathic) or secondary in origin, e.g., as part of a systemic disease or  
53 infection (1-5). Irrespective of the origin, IBrainD pathology is characterized by immune cell activation,  
54 inflammation, cytokine, and/or antibody production. Specific inflammatory pathways target different  
55 structures in the CNS (2, 6). Such structures may be certain segments of blood vessels and neurons or  
56 CNS proteins such as myelin, cell surface receptors, channels, or enzymes (6). Based on either the  
57 affected structures or the disease mechanism, IBrainDs may be classified as demyelinating, antibody-  
58 associated, T-cell mediated, granulomatous, or CNS vasculitis.

59 Overall, pediatric-onset IBrainDs are rare. Incidences are only known for a few subgroups, such as  
60 demyelinating diseases 0.05-2.85/100'000 persons/year (7-14). Other IBrainDs are presumed to occur  
61 even less frequently. However, epidemiological data, particularly on children, are lacking.

62 Rare diseases are inherently difficult to study. Their investigation requires special efforts and  
63 appropriate instruments. Patient registries are well suited to study the natural history of (rare) diseases;  
64 the Canadian pediatric demyelinating disease registry and BrainWorks – a Canadian registry for pediatric  
65 IBrainD patients – have markedly advanced the knowledge on IBrainDs in children (2, 6). Additionally,  
66 they have increased awareness and consecutively helped to improve the care of this vulnerable  
67 population.

68 Following their example, a national pediatric-onset IBrainD registry (Swiss-Ped-IBrainD) was founded in  
69 2019.

70 The primary focus of the Swiss-Ped-IBrainD is on the understudied areas in this field, such as  
71 epidemiology, health care management in general (and the diagnostic process in particular), as well as  
72 long-term patient outcomes.

73 Epidemiological data such as prevalence, incidence, or prognostic data are invaluable for recognition of  
74 pediatric-onset IBrainDs by the healthcare system. This may favor future policymaking which addresses  
75 pediatric-onset IBrainDs.

76 Pediatric-onset IBrainDs are often diagnosed with a significant delay, which entails a delay in treatment  
77 initiation. Optimizing the diagnostic process is one of our priorities since starting treatment early  
78 improves disease outcomes (3, 5, 6, 11) – particularly in demyelinating and antibody-mediated diseases.  
79 Researching the clinical phenotypes of pediatric-onset IBrainDs and gathering information on the  
80 diagnostic workup will help to differentiate the diseases and expedite the diagnosis.

81 In an acute phase the treatment of IBrainDs is directed at controlling the inflammation. Following the  
82 acute intervention, many patients receive specific immunomodulatory treatment depending on the  
83 inflammatory pathways of the underlying IBrainD (6). Despite appropriate treatment, some children  
84 develop functional deficits (3, 11). We will assess these functional deficits and other outcomes of  
85 pediatric-onset IBrainD patients and hope to identify relevant factors that may be implemented in new  
86 treatment guidelines.

87 Furthermore, the registry should enable patients with pediatric-onset IBrainDs to participate in  
88 international clinical studies for e.g., new drugs or new therapeutic regimens. Until now, these patients  
89 have rarely had the opportunity to participate in international studies – they were at a disadvantage  
90 compared to patients from countries with centralized registration such as France or Italy.

91 Through the Swiss-Ped-IBrainD registry and its linkage with other rare disease registries, we also expect  
92 to achieve high enough case numbers for statistically significant results.

## 93 Materials and methods

### 94 Main aims

95 The Swiss-Ped-IBrainD registry has three main aims.

96 Firstly, to provide detailed and comprehensive health reporting on pediatric-onset IBrainDs in  
97 Switzerland. The reporting includes but is not limited to the following areas of interest: epidemiology,  
98 demographics, diagnostics, management, and treatment.

99 Secondly, to promote research by cultivating a regular exchange between the study centers and  
100 providing investigators with access to the high-quality structural data collected by the registry.

101 Thirdly, to facilitate access to national and international studies for pediatric IBrainD patients living  
102 and/or treated in Switzerland.

### 103 Procedure

104 The Swiss-Ped-IBrainD Registry is a multicentric, population based, observational cohort study. The  
105 eleven neuropediatric centers in Switzerland shown in Figure 1 have agreed to participate.

106 *Figure 1: Participating Departments/Divisions of Neuropediatrics, Child Neurology and Neuropsychology*

107 We expect to detect close to 100% of new pediatric-onset IBrainD patients. Since pediatric-onset  
108 IBrainDs are severe conditions requiring expert care, most patients in Switzerland will seek help at or be  
109 referred to one of the participating specialized centers. Child neurologists in private practices in  
110 Switzerland do not treat IBrainD patients themselves (15); missing new patients with a pediatric-onset  
111 IBrainD is therefore highly unlikely.

112 Patient screening is conducted by the principal investigators (PIs) of the study centers. They compile a  
113 screening list and inform all regularly seen, eligible patients of the registry. Patients who do not pay  
114 regular visits to the centers (due to various reasons including transition to adult care, moving, and  
115 treatment conclusion) may be informed by letter. All informed patients are invited to consent to study  
116 participation by means of signing the informed consent form. If the patient is underage, their  
117 parent(s)/guardian(s) must also sign the informed consent form. Recruitment has started on the 1<sup>st</sup> of  
118 November 2020. As is typical for a medical registry, recruitment is open-ended and therefore has no  
119 fixed end date.

120 The signed consent form allows us to collect all of the patient's data (including identifying data) as  
121 defined in the case report forms. If patients or their families choose not to consent, we can still collect a  
122 de-identified minimal dataset including diagnosis, year of diagnosis, year of birth, sex, status (dead or  
123 alive) and cause of death, if applicable. This procedure has been approved by the local ethics committee  
124 to ensure the completeness of the epidemiological data.

125 The collected data is purely observational. Medical records are the primary data source.

126 The collection has retrospective and prospective components. Patient data from the time of diagnosis  
127 until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric  
128 IBrainD patients are recruited continuously. Their data as well as the follow-up data of formerly  
129 diagnosed patients are collected and updated regularly (prospective).

130 The data collection itself is centrally organized by the Executive Office, which is the operational arm of  
131 Swiss-Ped-IBrainD and is located at the Institute of Social and Preventive Medicine (ISPM) at the  
132 University of Bern. The Executive Office is responsible for the collection of patient data from all  
133 participating centers (central data collection). The Executive Office and the PIs work together to  
134 maintain a continuous flow of data from the participating centers into the Swiss-Ped-IBrainD database.



135 This includes establishing access to source documents and case report forms for the Executive Office  
136 and the transformation of this into a standardized process.

137 To promote joint research and advance patient management the Task Force on Patient Care and  
138 Management was founded. This working group meets bimonthly and is comprised of all PIs as well as  
139 additional experts in the field (neuropsychologists and neuroradiologists).

140 The Swiss-Ped-IBrainD further provides the basis for national surveys, since questionnaire studies in line  
141 with the objectives of the Swiss-Ped-IBrainD are covered by the ethical approval. We are currently  
142 preparing the first questionnaire on patient/family perceptions of the diagnostic process and quality of  
143 life.

#### 144 Study Population

145 Regarding the target population, we aim to include all pediatric-onset IBrainD patients living or treated  
146 in Switzerland who have been diagnosed since 2005 (Swiss population  $\leq 33$  years of age: 3'260'287  
147 (Statistik 2010)). Because epidemiological data on pediatric-onset IBrainDs is scarce, the number of  
148 eligible patients is merely a rough estimate. Incidences between 0.05-2.85/100'000 persons/year (7-14)  
149 have been reported for demyelinating diseases of the CNS and 0.04-0.33/100'000 persons/year (16, 17)  
150 for other IBrainDs such as pediatric-onset anti-NMDA receptor encephalitis. Considering these numbers  
151 and our single center experience we anticipate 300-400 eligible patients.

#### 152 Inclusion criteria

153 Patients living and/or treated in Switzerland diagnosed since 2005 with one of the pediatric-onset  
154 IBrainDs listed in Table 1.

155 *Table 1: Pediatric-onset inflammatory brain diseases to be included in the Swiss Pediatric Inflammatory Brain Disease Registry.*  
156 *The list of the included diagnoses might evolve over time given the active research in the field and validation of new techniques*  
157 *for diagnosis.*

Disease Family	Diagnosis
----------------	-----------

Demyelinating	Optic neuritis Transverse myelitis Acute disseminated encephalomyelitis Multiple sclerosis Neuromyelitis optica spectrum disorders
Antibody associated	Anti-NMDA-R Anti-GAD65 Anti-AMPA-1/2 Anti-Lgi-1 Anti-CASPR-2 Anti-GABA-1/2 Onconeuronal antibodies Hashimoto encephalopathy
T-cell mediated	Rasmussen's encephalitis
Other	CNS Vasculitis CNS Sarcoidosis CNS Lupus

158

### 159 Exclusion criteria

160 Patients with neurological symptoms due to infectious diseases of the CNS or congenital infections (such  
161 as TORCH, peripheral facial palsy), patients with genetic metabolic causes of central demyelinating  
162 diseases and patients with neurological symptoms due to Guillain-Barré-Syndrome will be excluded from  
163 participation.

### 164 Organization

165 Swiss-Ped-IBrainD has two main bodies: the Steering Board and the Executive Office.

166 The Steering Board consists of medical specialists, mainly pediatric neurologists, and has an elected  
167 President and Vice-President. It supervises the Executive Office and sets the direction.

168 The Executive Office, located at the ISPM, consists of the Co-Heads (Swiss-Ped-IBrainD Legal  
169 Representative and Clinical Lead), the Project Manager, the Data Manager and other team members. It  
170 manages the database, the variables, the archived documents, and the information on organization  
171 rules.

172 Other closely linked structures are the participating clinics and the Task Force on Patient Care and  
173 Management.

174 The main task of the participating clinics is to recruit patients and provide data to the Swiss-Ped-IBrainD.

175 The main task of the Task Force is to discuss complex cases, establish standards of care and work on

176 pressing issues in the field of pediatric-onset IBrainDs. Figure 1 shows the organization of the Swiss-Ped-

177 IBrainD and its associated structures.

178 *Figure 2: Organizational structure of the Swiss Pediatric Inflammatory Brain Disease Registry; PM: Project management; DM:*  
179 *Data management*

## 180 Ethics statement

181 This project was approved by the cantonal ethics committee of Bern (IRB number: 2019-00377) as well

182 as the ethics committees of Northwest and Central Switzerland, Ticino, Zürich, Geneva, Vaud, and East

183 Switzerland, which cover the 11 study centers. It is and will be conducted in accordance with the

184 protocol, the Declaration of Helsinki (18), the principles of Good Clinical Practice (19), the Human

185 Research Act (20) and the Human Research Ordinance (21) as well as other locally relevant regulations.

186 The Swiss-Ped-IBrainD will further adhere to the recent recommendations for health-related registries

187 elaborated by the National Association for Quality Development in Hospitals and Clinics, Swiss Medical

188 Association, Swiss Hospitals Association, Swiss Academy of Medical Sciences, and University Medicine

189 Switzerland (22). These recommendations serve as basis for quality assurance of registries.

## 190 Data management

191 We collect and archive all personal, medical, and questionnaire data as well as digitalized documents of

192 the project in a dedicated electronic data capturing system (REDCap ISPM UniBe). The database

193 complies with all requirements for data security and protection.

## 194 Statistical analysis plan

195 Since the registry has no designated endpoint, we will continuously analyze the collected data and  
196 update results according to our evolving objectives.

197 Initially, descriptive statistics (mean and standard deviation, median and range, summary tables and  
198 simple graphics) will serve to characterize pediatric-onset IBrainD patient population of Switzerland.

199 Subsequently, we plan to investigate between-group differences with tests such as t-tests, chi-squared,  
200 Wilcoxon-Mann, and Fisher's exact depending on the variables in question.

201 For more advanced analyses including associations between factors, we will use regression modelling  
202 (logistic, linear, Poisson). For follow-up data we will apply statistical methods appropriate for  
203 longitudinal data such as cox and Poisson regression or Kaplan-Meier survival curves.

204 We also intend to supplement our datasets with data from relevant routine data and other registries.

205 This allows conducting case-control studies or cohort-based studies about causes and the long-term  
206 course of pediatric-onset IBrainDs.

207 For all analyses we will use STATA (STATA Corp LP, Texas USA) and R (R Foundation for Statistical  
208 Computing, Vienna, Austria) or comparable statistical software.

## 209 Safety considerations

210 The project participation entails minimal risks and burdens (category A). We do not expect any safety  
211 issues and therefore refrain from implementing protective measures.

## 212 Current status

213 Currently, all 11 neuropediatric centers have been initiated and are recruiting. As of the first of May  
214 2023, we have identified 275 eligible participants and obtained 101 informed consents from patients  
215 and/or families. None of the informed patients and/or families have refused participation.

216 [Dissemination plan](#)

217 Results of this project will be published in scientific journals and presented at scientific conferences.

218 Authorship will be handled according to the ICMJE ([www.icmje.org](http://www.icmje.org)). Ongoing studies and short

219 summaries of the latest news are published on the project website. We will generate annual reports of

220 the Swiss-Ped-IBrainD.

## 221 Discussion

### 222 Potential problems and limitations

223 We want to reach completeness – meaning we want to collect data from the entire target population.

224 This is challenging since some patients, especially those with mild IBrainDs, may no longer require  
225 continued medical care. They are therefore difficult to find and reach (selection/recruitment bias).

226 However, we will exploit all available and legal measures to recruit as many patients as possible. To  
227 directly address and minimize the effect of selection/recruitment bias we will collect the minimal  
228 dataset from all identified patients after they have been informed.

229 Misclassification may be a further limitation. To reduce misclassification, we rely on an international  
230 classification system and results from biopsies, electrophysiological examinations, and specific  
231 laboratory testing (e.g., presence of disease-identifying antibodies such as NMDA-R-AB or NMO-IgG).  
232 Patients without a precise diagnosis will not be included. We will also run regular plausibility checks.

233 Missing data is a further limitation we foresee. To minimize data gaps in the medical history of the  
234 patients, we have centralized the data collection; a member of the Executive Office regularly visits the  
235 participating centers and collects patient data. These data-collection visits are also good opportunities  
236 to resolve open queries and monitor recruitment. Regarding data from questionnaires, we will remind  
237 patients to return their questionnaires. On the analysis level, we will use inverse probability weighting to  
238 account for an eventual attrition bias (23). This procedure gives more weight to well-explained  
239 observations (by baseline data) and thereby compensates for non-observed follow-up data. Missing data  
240 may also be computed by multiple imputation, as done in previous studies (24).

241 [Amendments and end of project](#)

242 Substantial changes to the project set-up, the protocol and relevant project documents will be

243 submitted to the responsible institutional review board for approval. This includes the distribution of

244 questionnaires to patients and families.

245 The project has no defined endpoint. However, the Swiss-Ped-IBrainD may be terminated or suspended

246 due to financial or personnel-related reasons.

## 247 Acknowledgements

248 We thank Lilianna Bolliger for important ground-laying work.



## 249 References

- 250 1. Cellucci T, Tyrrell PN, Twilt M, Soon GS, Yau I, Sheikh S, et al. Distinguishing features in the  
251 presentations of childhood inflammatory brain diseases at a tertiary-care centre. *Pediatric*  
252 *Rheumatology Online Journal*. 2012;10(Suppl 1):A81.
- 253 2. Liu E, Twilt M, Tyrrell PN, Dropol A, Sheikh S, Gorman M, et al. Health-related quality of life in  
254 children with inflammatory brain disease. *Pediatric Rheumatology Online Journal*. 2018;16(1):73.
- 255 3. Smitka M, Bruck N, Engellandt K, Hahn G, Knoefler R, von der Hagen M. Clinical Perspective on  
256 Primary Angiitis of the Central Nervous System in Childhood (cPACNS). *Frontiers in pediatrics*.  
257 2020;8:281.
- 258 4. Twilt M, Sheikh S, Benseler S. PRoS-FINAL-2362: The spectrum of childhood inflammatory brain  
259 diseases; an increasingly recognised field. *Pediatric Rheumatology Online Journal*. 2013;11(Suppl  
260 2):P352.
- 261 5. Twilt M, Benseler SM. CNS vasculitis in children. *Multiple sclerosis and related disorders*.  
262 2013;2(3):162-71.
- 263 6. Twilt M, Benseler SM. Childhood inflammatory brain diseases: pathogenesis, diagnosis and  
264 therapy. *Rheumatology (Oxford, England)*. 2014;53(8):1359-68.
- 265 7. Metz I, Weigand SD, Popescu BF, Frischer JM, Parisi JE, Guo Y, et al. Pathologic heterogeneity  
266 persists in early active multiple sclerosis lesions. *Annals of neurology*. 2014;75(5):728-38.
- 267 8. Pavone P, Pettoello-Mantovano M, Le Pira A, Giardino I, Pulvirenti A, Giugno R, et al. Acute  
268 disseminated encephalomyelitis: a long-term prospective study and meta-analysis. *Neuropediatrics*.  
269 2010;41(6):246-55.
- 270 9. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS  
271 demyelinating syndromes in a multiethnic cohort of children. *Neurology*. 2011;77(12):1143-8.
- 272 10. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KG, Eikelenboom MJ,  
273 et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study.  
274 *Journal of neurology*. 2012;259(9):1929-35.
- 275 11. Bigi S, Hladio M, Twilt M, Dalmau J, Benseler SM. The growing spectrum of antibody-associated  
276 inflammatory brain diseases in children. *Neurology(R) neuroimmunology & neuroinflammation*.  
277 2015;2(3):e92.
- 278 12. Burton KLO, Williams TA, Catchpoole SE, Brunsdon RK. Long-Term Neuropsychological Outcomes  
279 of Childhood Onset Acute Disseminated Encephalomyelitis (ADEM): a Meta-Analysis. *Neuropsychology*  
280 *review*. 2017;27(2):124-33.
- 281 13. Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic  
282 Review of the Literature. *Journal of child neurology*. 2019;34(12):705-12.
- 283 14. Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: A  
284 systematic literature review and meta-analysis. *Multiple sclerosis and related disorders*.  
285 2020;44:102260.
- 286 15. Hofer S, Bauder F, Capone Mori A, Chan A, Dill P, Garcia-Tarodo S, et al. Management of Acute  
287 Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. *Clinical and*  
288 *Translational Neuroscience*. 2021;5(2):17.
- 289 16. Giri YR, Parrill A, Damodar S, Fogel J, Ayed N, Syed M, et al. Anti-N-Methyl-D-Aspartate Receptor  
290 (NMDAR) Encephalitis in Children and Adolescents: A Systematic Review and Quantitative Analysis of  
291 Reported Cases. *Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de*  
292 *l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent*. 2021;30(4):236-48.

- 293 17. Ho AC, Chan SH, Chan E, Wong SS, Fung ST, Cherk SW, et al. Anti-N-methyl-d-aspartate receptor  
294 encephalitis in children: Incidence and experience in Hong Kong. *Brain & development*. 2018;40(6):473-  
295 9.
- 296 18. Association WM. World Medical Association Declaration of Helsinki: ethical principles for  
297 medical research involving human subjects. *Jama*. 2013;310(20):2191-4.
- 298 19. (ICH) ICfHoTRfPpFHU. INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL  
299 PRACTICE E6(R2). 2016.
- 300 20. (KAV) SB. Bundesgesetz über die Forschung am Menschen (Humanforschungsgesetz, HFG;  
301 Human Research Act. 2013.
- 302 21. (KAV) SB. Verordnung über die Humanforschung mit Ausnahme der klinischen Versuche  
303 (Humanforschungsverordnung, HFV): Human Research Ordinance. In: *Gesundheit Bf*, editor. 2013.
- 304 22. Busch P, Heller R, Hofstetter A, Clerc V, Kern A, Nienhaus A, et al. Recommendations for the  
305 development and operation of health-related registries. 2.0 ed2019.
- 306 23. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding  
307 in Observational Studies. *Multivariate behavioral research*. 2011;46(3):399-424.
- 308 24. Dogaru CM, Strippoli MP, Spycher BD, Frey U, Beardsmore CS, Silverman M, et al. Breastfeeding  
309 and lung function at school age: does maternal asthma modify the effect? *American journal of*  
310 *respiratory and critical care medicine*. 2012;185(8):874-80.

311




Figure 1




Figure 2